Positive.

From Investing.: 2024-10-12 05:00:00

Weight-loss medications like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro are a hot topic in the healthcare sector, with record profits for both companies. Global sales for GLP-1 drugs could reach $150 billion by the next decade, leading to high demand. Over 74% of US adults are overweight or obese, creating a growing market for weight-loss drugs driven by cost-benefit economics. GLP-1 medications may also benefit other health issues like cardiovascular risk, sleep apnea, and dementia, providing a favorable outlook for the healthcare sector overall.



Read more at Investing.: GLP-1 drugs the “most compelling story in healthcare sector”